While the trial showed potential additive benefits when combined with SGLT2 inhibitors (SGLT2i) or finerenone, conclusive evidence for these effects is lacking
The mean weight loss with cagrilintide 0.34.5 mg ranged from 5.0% to 9.8% at week 32 compared with 6.1% to 10.8% at week 26
Until Retatrutide receives FDA approval, approved treatments like Wegovy and Zepbound, with assistance from Klinic's healthcare providers in Oswego, New York, remain the best option
CJC-1295 : Dosage is generally less frequent, with standard administration ranging from 1-2 mg per week
Lower levels are better, and a common treatment goal is to reduce HbA1c to below 53 mmol/mol (7%)
Patients with prediabetes, type 2 diabetes, or significant weight loss goals should consult a qualified healthcare provider to evaluate whether prescription GLP-1 therapy, lifestyle modifications, or precision diagnostics (like genetic testing) are more appropriate